Fluoroquinolone Antibiotics Receive Updated FDA Warnings

by Madhumathi Palaniappan on  July 28, 2016 at 4:50 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The United States Food and Drug Administration has approved safety labeling changes for a specific class of antibiotics called Fluoroquinolones. These antibiotic drugs are capable of causing serious side effects that may result in disability of muscles, joints, tendons and central nervous system.
Fluoroquinolone Antibiotics Receive Updated FDA Warnings
Fluoroquinolone Antibiotics Receive Updated FDA Warnings

Fluoroquinolone antibiotics are used to kill or inhibit the growth of bacteria. They usually fight against bacterial infections. Drugs like levofloxacin, ciprofloxacin, moxifloxacin, ofloxacin and gemifloxacin are approved by the FDA for the treatment of bacterial infections.

However, the FDA safety review has listed oral and injectable fluoroquinolones being associated with permanent side effects resulting in disability which is linked to muscles, nerves, tendons and joints. These side effects may occur immediately or after few weeks of the treatment with antibiotics.

The FDA has thus reserved the use of fluoroquinolone antibiotics only for conditions like anthrax, bacterial pneumonia which has no alternative treatment options. These drugs are generally used for conditions where the benefits of the drug outweigh the risk factors and adverse effects.

The labeling changes include categories like boxed warnings, contraindications, warnings and precautions, adverse reactions and patient prescription information or medication guide for the safe use of medicines.

The first boxed warning for fluoroquinolones was given in 2008 for an increased risk of tendonitis and tendon rupture followed by another in 2011 due to the worsening symptoms in myasthenia gravis patients.

In 2015, the FDA advisory committee discussed on the serious side effects and benefits of fluoroquinolone antibiotics for uncomplicated infections like bacterial sinusitis, bronchitis and urinary tract infections and concluded that the risks of permanent impairement outweighed the benefits of the drug in these conditions.

Hence the FDA has recently warned the use of fluoroquinolone antibiotics for these conditions. The new safety information will be updated in the drug labels.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

MRSA - The Super Bug Antibiotics Eye Infections Natural Antibiotics to Fight Bacterial Infections Vancomycin-Resistant Enterococci (VRE) Boils - Treatment by Drugs Multiple Drug Allergy Syndrome Interaction of Antibiotics with Dairy Products 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive